What is the 13F Pro Quality Score for BAX?

13F Pro ranks BAXTER INTERNATIONAL INC (BAX) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View BAX's current score at https://13fpro.ai/research/BAX (free sign-up required for the full ranking).

Which hedge funds own the most BAX stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of BAX include BlackRock,, PZENA INVESTMENT MANAGEMENT, DODGE & COX. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/research/BAX as soon as new 13F filings post.

Where does 13F Pro source BAX data?

All BAXTER INTERNATIONAL INC fundamentals and ownership data come directly from SEC EDGAR. BAXTER INTERNATIONAL INC files with the SEC under CIK 10456. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is BAX in?

BAXTER INTERNATIONAL INC (BAX) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is BAX research updated on 13F Pro?

BAX's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

BAXTER INTERNATIONAL INC(BAX)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →NYSE

Institutional-grade research for retail investors

SEC EDGAR: CIK 10456 BAX stock profile & AI dashboard →

13F Pro Quality Score

45.7/100

Rank #1,701 of 2,879 stocks

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Aug 14, 2026.

Revenue Growth

47.7/100

Profitability

30.0/100

Balance Sheet

41.6/100

Earnings Quality

1.0/100

Free Cash Flow

48.6/100

Institutional Flow

14.4/100

Revenue Scale

87.2/100

Dilution Risk

56.2/100

BAX Stock Analysis & AI Quality Score

AI stock analysis and institutional research for BAXTER INTERNATIONAL INC (BAX), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores BAX at 45.7/100 on a 32-signal composite quality model, placing it at rank #1,701 of 2,879 stocks — the bottom half of the AI-ranked universe. BAX scores in the top quartile across revenue scale (87.2). Areas of concern include earnings quality (1.0) and institutional flow (14.4), which score below median versus the broader universe. Based on the latest XBRL financial filings (Q1 2026), BAXTER INTERNATIONAL INC reports quarterly revenue of $2.7B, net income of $-15.0M, free cash flow of $213.0M. Top institutional holders of BAX by reported 13-F value include BlackRock,, PZENA INVESTMENT MANAGEMENT, DODGE & COX, based on the most recent SEC filings. BAX trades on the NYSE exchange and files with the SEC under CIK 10456. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate BAX daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for BAXTER INTERNATIONAL INC directly from SEC EDGAR. BAXTER INTERNATIONAL INC's 13F Pro composite quality score has ranged between 8 and 68 since 2021, currently 45.7 — a declining long-term trajectory across 56 quarterly and live scoring snapshots.

✦

Fun facts about BAXTER INTERNATIONAL INC

Quirks, history, and lore behind BAX — the kind of stuff that makes a stock memorable.

1
The Basics
U.S. healthcare company · large-cap · listed on the NYSE · headquartered in Illinois.
2
The Numbers
Annual revenue in the range of $15–17 billion, with operations spanning over 100 countries — a genuinely global medical supplier.
3
The History
Founded in the 1930s, it was an early pioneer in intravenous solutions and helped transform hospital care by making IV therapy a clinical standard.
4
The Secret
It spun off its kidney-care division as a separate public company in 2021, betting that two focused businesses beat one sprawling one.
5
The Lore
Walk into almost any hospital and you'll find its IV bags, infusion pumps, and renal dialysis equipment — the unglamorous plumbing that keeps patients alive.
6
The Giveaway
Its name sounds like a fancy British law firm, but it's really the company quietly hanging IV bags in hospitals worldwide — ticker BAX.

▶ Think you know your stocks? Play the Daily Ticker

Revenue

Q1 2026

$2.7B

Net Income

Q1 2026

$-15.0M

Free Cash Flow

Q1 2026

$213.0M

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

+5.7% YoY

$11.24BFY 2025

FY22 $10.06BFY23 $10.36BFY24 $10.64BFY25 $11.24B

Net Income

-47.5% YoY

$-957.0MFY 2025

FY22 $-2.43BFY23 $2.66BFY24 $-649.0MFY25 $-957.0M

Operating Income

-2300.0% YoY

$-308.0MFY 2025

FY22 $-2.85BFY23 $707.0MFY24 $14.0MFY25 $-308.0M

EPS (Diluted)

-47.2% YoY

$-1.87FY 2025

FY22 $-4.83FY23 $5.23FY24 $-1.27FY25 $-1.87

Total Assets

-22.2% YoY

$20.05BFY 2025

FY22 $28.29BFY23 $28.28BFY24 $25.78BFY25 $20.05B

Total Debt

-40.5% YoY

$9.48BFY 2025

FY22 $18.11BFY23 $16.52BFY24 $15.93BFY25 $9.48B

Op. Cash Flow

-17.1% YoY

$845.0MFY 2025

FY22 $1.21BFY23 $1.73BFY24 $1.02BFY25 $845.0M

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2019
Revenue	$11.24B +5.7%	$10.64B +2.7%	$10.36B +3.0%	$10.06B -17.2%	$12.15B +6.9%	$11.36B
Net Income	$-957.0M -47.5%	$-649.0M -124.4%	$2.66B +209.2%	$-2.43B -289.5%	$1.28B +28.3%	$1.00B
Operating Income	$-308.0M -2300.0%	$14.0M -98.0%	$707.0M +124.9%	$-2.85B -310.7%	$1.35B -23.8%	$1.77B
EPS (Diluted)	$-1.87 -47.2%	$-1.27 -124.3%	$5.23 +208.3%	$-4.83 -290.9%	$2.53 +31.1%	$1.93
Total Assets	$20.05B -22.2%	$25.78B -8.8%	$28.28B -0.0%	$28.29B -15.6%	$33.52B +84.3%	$18.19B
Total Debt	$9.48B -40.5%	$15.93B -3.6%	$16.52B -8.7%	$18.11B -0.9%	$18.27B +241.4%	$5.35B
Operating Cash Flow	$845.0M -17.1%	$1.02B -41.0%	$1.73B +42.5%	$1.21B -45.5%	$2.22B +5.6%	$2.10B

Get alerted when BAX's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for BAXTER INTERNATIONAL INC including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of BAX

BlackRock, Inc.
$1.3B79,400,664 sh
PZENA INVESTMENT MANAGEMENT LLC
$1.1B64,527,823 sh
DODGE & COX
$961.9M57,254,570 sh
FMR LLC
$777.2M46,264,804 sh
VANGUARD CAPITAL MANAGEMENT LLC
$562.9M33,506,975 sh
VANGUARD PORTFOLIO MANAGEMENT LLC
$403.1M23,993,355 sh
STATE STREET CORP
$335.9M19,979,957 sh
GREENHAVEN ASSOCIATES INC
$240.4M14,307,688 sh
GEODE CAPITAL MANAGEMENT, LLC
$230.8M13,762,965 sh
Invesco Ltd.
$220.4M13,121,171 sh

Fund	Value	Shares
BlackRock, Inc.	$1.3B	79,400,664
PZENA INVESTMENT MANAGEMENT LLC	$1.1B	64,527,823
DODGE & COX	$961.9M	57,254,570
FMR LLC	$777.2M	46,264,804
VANGUARD CAPITAL MANAGEMENT LLC	$562.9M	33,506,975
VANGUARD PORTFOLIO MANAGEMENT LLC	$403.1M	23,993,355
STATE STREET CORP	$335.9M	19,979,957
GREENHAVEN ASSOCIATES INC	$240.4M	14,307,688
GEODE CAPITAL MANAGEMENT, LLC	$230.8M	13,762,965
Invesco Ltd.	$220.4M	13,121,171

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put BAX on your watchlist

Track score changes the day BAXTER INTERNATIONAL INC files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is BAX a good stock to buy?

13F Pro's AI-powered analysis of BAXTER INTERNATIONAL INC (BAX) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on NYSE). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for BAX are available on the BAX stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own BAX?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling BAX. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of BAXTER INTERNATIONAL INC's investment landscape.